[ad_1]
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into CytoDyn Inc. (OTC:CYDY).
Beginning in early 2020, the Company began pivoting its existing drug candidate, leronlimab, which was originally developed for the treatment of HIV, for use as a treatment for severe cases of COVID-19. On March 5, 2021, the Company issued a press release purporting to tout the positive trial results of leronlimab, stating in part, that “the Phase 3 trial of leronlimab for the treatment of severe-to-critical patients with COVID-19 demonstrated continued safety, substantial improvement in the survival rate, and . ..
Full story available on Benzinga.com
[ad_2]
Source link
